Organization Overview
Alternative names
alemtuzumab (campath) (1 trial)
allogeneic bone marrow (3 trials)
allogeneic cord blood (2 trials)
allogeneic stem cells (1 trial)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (5 trials)
autologous hematopoietic stem cells (2 trials)
bone marrow derived mononuclear cells (1 trial)
cyclophosphamide (cytoxan) (12 trials)
cyclosporine (sandimmune) (2 trials)
allogeneic hematopoietic stem cells (Hemacord) (5 trials)
bone marrow derived mesenchymal stem cells (1 trial)
cytarabine (cytosar-u) (1 trial)
dendritic cell tumor fusion vaccine (1 trial)
Adenoviridae Infections (Phase 2)
Anemia (Phase 2)
Anemia, Aplastic (Phase 2)
Anemia, Diamond-Blackfan (Phase 3)
Anemia, Sickle Cell (Phase 3)
Burkitt Lymphoma (Phase 3)
Communicable Diseases (Phase 3)
Epstein-Barr Virus Infections (Phase 2)
Graft vs Host Disease (Phase 3)
Granulomatous Disease, Chronic (Phase 2)
Hemoglobinopathies (Phase 3)
Immunologic Deficiency Syndromes (Phase 2)
Infections (Phase 3)
Leukemia (Phase 3)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Lymphohistiocytosis, Hemophagocytic (Phase 2)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Mantle-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 3)
Multiple Myeloma (Phase 3)
Mycoses (Phase 3)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 3)
Neoplasm, Residual (Phase 2)
Neoplasms, Plasma Cell (Phase 3)
Neutropenia (Phase 3)
Pneumonia (Phase 3)
Preleukemia (Phase 3)
Syndrome (Phase 3)
Thalassemia (Phase 3)
Tissue Adhesions (Phase 2)
Virus Diseases (Phase 2)